EUVIMEDEUVIMED entdecken
Crossref

Recurrence morbidity of olfactory neuroblastoma

Katie Melder, Jess C Mace, Garret Choby iD, Joao Paulo Almeida, Pierre-Olivier Champagne, Erik Chan, Jeremy Ciporen, Mark B Chaskes, Juan Fernandez-Miranda, Nicholas K Fung, Paul Gardner, Peter Hwang iD und 15 weitere

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Katie Melder und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Louisiana State University, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Esthesioneuroblastoma, Olfactory, Nose Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease‐specific survival (DSS), and further recurrence.

Methods

A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time‐to‐event analyses.

Results

A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage ( p < 0.001), overall stage ( p < 0.001), and modified Kadish scores ( p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5‐year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.

Conclusions

Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esthesioneuroblastoma, OlfactoryNose NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultNasal CavityPrognosisNeoplasm Staging

Stichwörter der Autor:innen

esthesioneuroblastomaolfactory neuroblastomarecurrencesinonasal malignancyskull base

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Louisiana State University, New Orleans, Louisiana, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Neurological Surgery, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurological Surgery, Université Laval, Quebec, Quebec, Canada.
  • Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Garret Choby, Peter Hwang, Zara Patel, Carl Snyderman, Eric W Wang

Zitieren

APA

Melder, K., Mace, J. C., Choby, G., Almeida, J. P., Champagne, P. O., Chan, E., Ciporen, J., Chaskes, M. B., Fernandez-Miranda, J., Fung, N. K., Gardner, P., Hwang, P., Ji, K. S. Y., Kalyvas, A., Kong, K. A., Patel, C., Patel, Z., Celda, M. P., Pinheiro-Neto, C. D., …, & Geltzeiler, M. (2024). Recurrence morbidity of olfactory neuroblastoma. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23351

Vancouver

Melder K, Mace JC, Choby G, Almeida JP, Champagne PO, Chan E, et al. Recurrence morbidity of olfactory neuroblastoma. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23351

BibTeX
@article{Melder2024,
  author = {Melder, Katie and Mace, Jess C and Choby, Garret and Almeida, Joao Paulo and Champagne, Pierre-Olivier and Chan, Erik and Ciporen, Jeremy and Chaskes, Mark B and Fernandez-Miranda, Juan and Fung, Nicholas K and Gardner, Paul and Hwang, Peter and Ji, Keven Seung Yong and Kalyvas, Aristotelis and Kong, Keonho A and Patel, Chirag and Patel, Zara and Celda, Maria Peris and Pinheiro-Neto, Carlos D and Snyderman, Carl and Thorp, Brian D and Van Gompel, Jamie J and Zenonos, Georgios and Zwagerman, Nathan T and Sanusi, Olabisi and Wang, Eric W and Geltzeiler, Mathew},
  title = {Recurrence morbidity of olfactory neuroblastoma},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23351}
}
Kostenlos starten →